Citations

Clear

9383 citation(s) found for "Thomas, PS".

Young Adolescent With Restricted Arm Motion During a Preparticipation Physical Exam
Potts, Audrey A. , McLachlan, Madison L., Stoll, Rebecca , Billings, Thomas A., Miller, Nathaniel E. , Stoll, Rebecca J, Billings, Thomas, Miller, Nathaniel E , Potts, A. , McLachlan, Madison L., Billings, Thomas

Mayo Clinic

Journal of Primary Care & Community Health | September 15, 2023 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/21501319231201092 | PMID 37714822 Get It

A healthy 15-year-old right-hand dominant football player presented to the clinic for a preparticipation examination (PPE) with an exam notable for reduced right shoulder range of motion. The patient reported no complaints, including no pain. Upon questioning, he noted a remote non-sports related injury to that shoulder with unremarkable radiographs at that time. Subsequent X-ray imaging showed a bony abnormality thought to be consistent with an osteochondroma. However, advanced imaging identified it as a heterotrophic ossification center that required a complex, multidisciplinary surgical team to correct. This case of a high school football player’s routine PPE that resulted in surgery highlights not only whether sport participation is safe, but also the importance of direct, specific language that asks about the history of any injuries, rather than specifically sports related.
Description of Cryptococcosis Following SARS-CoV-2 Infection: A Disease Survey Through the Mycosis Study Group Education and Research Consortium (MSG-19)
McCarty, Todd P , Ordaya, Eloy E. , Vergidis, Paschalis , Mammadova, Mehriban, Perfect, John R. , Messina, Julia A. , Vilchez, Gabriel, McMullen, Rachel, Jones, Carolynn Thomas , Pappas, Peter G. , Nigo, Masayuki , Steinbrink, Julie M. , Cahuayme‐Zuniga, Lizbeth , Vootukuri, Shobha, Onyeaghala, Chizaram , Ta, Tuan, Kale, Pratibha , Franklin, Alexander , Gandhi, Ravi H. , Ostrander, Darin , Thomas, Lora D. , Obeid, Karam M. , Sochanska, Ada, Klausing, Benjamin T, El-Herte, Rima , Tirmizi, Amir, Traver, Edward C , Osborn, Rebecca C., Mounajjed, Mark, McCarty, T P , Jones, Carolynn T , Vergidis, Paschalis , Obeid, Karam M , Walker, Jeremey B. , McGwin, Gerald , Ostrosky‐Zeichner, Luis , Spec, Andrej , Rauseo, Adriana M. , Yetmar, Zachary A. , Vootukuri, Shobha R, Gandhi, Ravi, Miceli, Marisa H. , Warner, Nathaniel C. , Hoz, Ricardo M. La , Thompson, George R , Gorsline, Chelsea A. , Sivasubramanian, Geetha , Osborn, Rebecca

Mayo Clinic

Clinical Infectious Diseases | September 15, 2023 | Volume: 78 | Issue: 2 | Pages: 371-377

10.1093/cid/ciad551 | PMID 37713207 Get It

Abstract Background Invasive fungal infections have been described throughout the COVID-19 pandemic. Cryptococcal disease after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been reported in several isolated case reports and 1 larger case series. We sought to describe cryptococcal infections following SARS-CoV-2 through establishing a database to investigate underlying risk factors, disease manifestations, and outcomes. Methods We created a crowdsourced call for cases solicited through the Mycoses Study Group Education and Research Consortium, the Centers for Disease Control and Prevention Emerging Infectious Diseases Network, and infectious diseases Twitter groups. Data were collected in a web-based and secure REDCap survey without personal identifiers. Results Sixty-nine cases were identified and submitted by 29 separate institutional sites. Cryptococcosis was diagnosed a median of 22 days (interquartile range, 9–42 days) after SARS-CoV-2 infection. Mortality among those with available follow-up was 72% (26/36) for the immunocompetent group and 48% (15/31) for the immunocompromised group (likelihood ratio, 4.01; P = .045). We observed a correlation between disease manifestation (central nervous system infection, proven/probable disseminated disease, and respiratory) and mortality (P = .002). Conclusions The mortality rate of 59% for patients with cryptococcosis following SARS-CoV-2 is higher than that of modern Cryptococcus cohorts. There was an association between immunocompromised status and cryptococcal disease manifestations as well as mortality. Moreover, our series emphasizes the need for clinical and laboratory assessment of opportunistic infections beyond 30 days when concerning symptoms develop.
Florida-California Cancer Research, Education and Engagement (CaRE 2 ) Health Equity Center: Structure, Innovations, and Initial Outcomes
Reams, Renee, Carpten, John D. , Redda, Kinfe K. , Aparicio, Jose , Hensel, Brooke , Askins, Nissa, Abreu, Andre, Adams, Angela, Agyare, Edward , Ali, Jamel , Aló, Richard, Báezconde‐Garbanati, Lourdes , Brant, Jason O. , Brown, Clyde , Ezenwa, Miriam O. , Falzarano, Sara M. , Flores‐Rozas, Hernan , Fredenburg, Kristianna M. , Huang, Yong , Kiros, Gebre-Egziabher , Lamango, Nazarius S. , Lee, Ji‐Hyun , Lyon, Debra , Mitchell, Duane A. , Mochona, Bereket , Laird‐Offringa, Ite A. , Parker, Alexander S. , Richey, Joyce M., Rogers, Sherise C. , Salhia, Bodour , Schmittgen, Thomas D. , Segal, Richard , Smith, Ukamaka D. , Su, Li‐Ming , Suther, Sandra , Treviño, José G. , Velazquez‐Villarreal, Enrique , Webb, Fern J. , Wu, Anna H. , Yao, Yingwei , Wilkie, Diana J. , Hensel, Brooke , George, Thomas J , Velazquez-Villarreal, Enrique I , Wilkie, Diana J , Stern, Mariana Carla , Krieger, Janice L. , Allen, John M. , Buxbaum, Sarah G. , Cohen, Pinchas , Cozen, Wendy , Fillingim, Roger Benton , George, Thomas J. , Han, Bo , Halbert, Chanita Hughes , Nieva, Jorgé , Okunieff, Paul G , Rhie, Suhn K. , Setiawan, Veronica Wendy

Mayo Clinic

Cancer Control | September 13, 2023 | Volume: 30 | Issue: No issue available | Pages: No page available

10.1177/10732748231197878 | PMID 37703814 Get It

Introduction The Florida-California Cancer Research, Education, and Engagement (CaRE 2 ) Health Equity Center is a triad partnership committed to increasing institutional capacity for cancer disparity research, the diversity of the cancer workforce, and community empowerment. This article provides an overview of the structure, process innovations, and initial outcomes from the first 4 years of the CaRE 2 triad partnership. Methods CaRE 2 serves diverse populations in Florida and California using a “molecule to the community and back” model. We prioritize research on the complex intersection of biological, environmental, and social determinants health, working together with scientific and health disparities communities, sharing expertise across institutions, bidirectional training, and community outreach. Partnership progress and outcomes were assessed using mixed methods and four Program Steering Committee meetings. Results Research capacity was increased through development of a Living Repository of 81 cancer model systems from minority patients for novel cancer drug development. CaRE 2 funded 15 scientific projects resulting in 38 publications. Workforce diversity entailed supporting 94 cancer trainees (92 URM) and 34 ESIs (32 URM) who coauthored 313 CaRE 2 -related publications and received 48 grants. Community empowerment was promoted via outreaching to more than 3000 individuals, training 145 community cancer advocates (including 28 Community Scientist Advocates), and publishing 10 community reports. CaRE 2 members and trainees together have published 639 articles, received 61 grants, and 57 awards. Conclusion The CaRE 2 partnership has achieved its initial aims. Infrastructure for translational cancer research was expanded at one partner institution, and cancer disparities research was expanded at the two cancer centers.
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors
Abuzakhm, Sonia, Sukrithan, Vineeth , Fruth, Briant, Qin, Rui , Strosberg, Jonathan , Hobday, Timothy J. , Reidy‐Lagunes, Diane , Kindler, Hedy L. , Kim, George P., Knox, Jennifer J. , Kaubisch, Andreas , Villalona‐Calero, Miguel A. , Erlichman, Charles , Shah, Manisha H. , Strosberg, Jonathan R , Knox, Jennifer J , Sukrithan, Vineeth , Semrad, Thomas John , Chen, Helen

Mayo Clinic

Endocrine-Related Cancer | September 13, 2023 | Volume: 30 | Issue: 11 | Pages: No page available

10.1530/erc-22-0301 | PMID 37702588 Get It

We assessed the efficacy and safety of combining bevacizumab with temsirolimus in patients with advanced extra-pancreatic neuroendocrine tumors. This NCI-sponsored multicenter, open-label, phase II study (NCT01010126) enrolled patients with advanced, recurrent, or metastatic extra-pancreatic neuroendocrine tumors. All patients were treated with temsirolimus and bevacizumab until disease progression or unacceptable toxicity. Temsirolimus 25 mg was administered i.v. on days 1, 8, 15, and 22 and bevacizumab 10 mg/kg i.v. on days 1 and 15 of a 4-week cycle. Discontinuation of temsirolimus or bevacizumab did not require discontinuation of the other agent. The primary endpoints were objective response rate and 6-month progression-free survival rate. Fifty-nine patients were enrolled in this study, and 54 were evaluated for efficacy and adverse events. While median progression-free survival was 7.1 months, the median duration of treatment with temsirolimus was 3.9 months and that with bevacizumab was 3.5 months. The objective response rate of combination therapy was 2%, and 6-month progression-free survival was 48%. The most frequently reported grade 3–4 adverse events included fatigue (13%), hypertension (13%), and bleeding (13%). Close to 54% of the patients discontinued treatment due to adverse events, refusal of further treatment, or treatment delays. Three deaths occurred in the study, of which two were due to treatment-related bowel perforations. Given the minimal efficacy and increased toxicity seen with the combination of bevacizumab and temsirolimus, we do not recommend the use of this regimen in patients with advanced extra-pancreatic neuroendocrine tumors.
Physical Resilience as a Predictor of Lifespan and Late-Life Health in Genetically Heterogeneous Mice
Brown, Ashley K. , Mazula, Daniel L., Roberts, Lori, Roos, Carolyn M, Pearsall, Vesselina, Schafer, Marissa , White, Thomas A. , Huang, Runqing, Kumar, Navasuja , Miller, Richard A. , Roos, Carolyn, Pearsall, Vesselina M, Miller, Jordan D. , Schafer, Marissa J , Zhang, Bin , LeBrasseur, Nathan K.

Mayo Clinic

The Journals of Gerontology: Series A | September 13, 2023 | Volume: 79 | Issue: 1 | Pages: No page available

10.1093/gerona/glad207 | PMID 37701988 Get It

Abstract Dynamic measures of resilience—the ability to resist and recover from a challenge—may be informative of the rate of aging before overt manifestations such as chronic disease, disability, and frailty. From this perspective mid-life resilience may predict longevity and late-life health. To test this hypothesis, we developed simple, reproducible, clinically relevant challenges, and outcome measures of physical resilience that revealed differences between and within age groups of genetically heterogeneous mice, and then examined associations between mid-life resilience and both lifespan and late-life measures of physiological function. We demonstrate that time to recovery from isoflurane anesthesia and weight change following a regimen of chemotherapy significantly differed among young, middle-aged, and older mice, and were more variable in older mice. Females that recovered faster than the median time from anesthesia (more resilient) at 12 months of age lived 8% longer than their counterparts, while more resilient males in mid-life exhibited better cardiac (fractional shortening and left ventricular volumes) and metabolic (glucose tolerance) function at 24 months of age. Moreover, female mice with less than the median weight loss at Day 3 of the cisplatin challenge lived 8% longer than those that lost more weight. In contrast, females who had more weight loss between Days 15 and 20 were relatively protected against early death. These data suggest that measures of physical resilience in mid-life may provide information about individual differences in aging, lifespan, and key parameters of late-life health.
CYP2D6 ‐guided opioid therapy for adults with cancer pain: A randomized implementation clinical trial
Mosley, Scott A. , Cicali, Emily J. , Cueto, Alex Del, Portman, Diane , Donovan, Kristine A. , Gong, Yan , Langaee, Taimour , Gopalan, Priya, Schmit, Jessica M., Starr, Jason S. , Silver, Natalie L. , Chang, Young D. , Rajasekhara, Sahana , Smith, Joshua E., Clare‐Salzler, Michael , Starostik, Petr , McLeod, Howard L. , Hicks, J. Kevin , Cicali, Emily , George, Thomas J , Hicks, J Kevin , Cavallari, Larisa H , Soares, Heloisa P. , George, Thomas J. , Fillingim, Roger Benton , Cavallari, Larisa H.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | September 12, 2023 | Volume: 43 | Issue: 12 | Pages: 1286-1296

10.1002/phar.2875 | PMID 37698371 Get It

Abstract Introduction The CYP2D6 enzyme metabolizes opioids commonly prescribed for cancer‐related pain, and CYP2D6 polymorphisms may contribute to variability in opioid response. We evaluated the feasibility of implementing CYP2D6 ‐guided opioid prescribing for patients with cancer and reported pilot outcome data. Methods Adult patients from two cancer centers were prospectively enrolled into a hybrid implementation‐effectiveness clinical trial and randomized to CYP2D6 ‐genotype‐guided opioid selection, with clinical recommendations, or usual care. Implementation metrics, including provider response, medication changes consistent with recommendations, and patient‐reported pain and symptom scores at baseline and up to 8 weeks, were assessed. Results Most (87/114, 76%) patients approached for the study agreed to participate. Of 85 patients randomized, 71% were prescribed oxycodone at baseline. The median (range) time to receive CYP2D6 test results was 10 (3–37) days; 24% of patients had physicians acknowledge genotype results in a clinic note. Among patients with CYP2D6 ‐genotype‐guided recommendations to change therapy ( n = 11), 18% had a change congruent with recommendations. Among patients who completed baseline and follow‐up questionnaires ( n = 48), there was no difference in change in mean composite pain score (−1.01 ± 2.1 vs. −0.41 ± 2.5; p = 0.19) or symptom severity at last follow‐up (3.96 ± 2.18 vs. 3.47 ± 1.78; p = 0.63) between the usual care arm ( n = 26) and genotype‐guided arm ( n = 22), respectively. Conclusion Our study revealed high acceptance of pharmacogenetic testing as part of a clinical trial among patients with cancer pain. However, provider response to genotype‐guided recommendations was low, impacting assessment of pain‐related outcomes. Addressing barriers to utility of pharmacogenetics results and clinical recommendations will be critical for implementation success.
Comparison of clinical features between patients with anti-synthetase syndrome and dermatomyositis: results from the MYONET registry
Hum, Ryan Malcolm , Lamb, Janine A. , Oldroyd, Alexander , Wang, Guochun , Wedderburn, Lucy R, Diederichsen, Louise Pyndt , Schmidt, Jens , Danieli, Maria Giovanna , Oakley, Paula, Griger, Zoltán , Phuong, Thuy Nguyen Thi , Kodishala, Chanakya , Mercado, Mónica Vázquez-Del , Andersson, Helena , Paepe, Boél De , Maurer, Britta , McCann, Liza , Pipitone, Nicolò , McHugh, Neil , New, Robert P, Ollier, William , Krogh, Niels Steen , Lundberg, Ingrid E. , Chinoy, Hector , Registry, MYONET, D’hose, Sophie, Lu, Xin , Tian, Xiaolan , Pleštilová, Lenka, Barochová, Tereza, Kubínová, Kateřina , Gelardi, Chiara, Paladini, Alberto , Piga, Mario Andrea , Jara, Luis J. , Cruz‐Reyes, Claudia , Andrade-Ortega, Lilia, Medrano-Ramírez, Gabriel , Salazar-Páramo, Mario , Chavarría-Ávila, Efrain , Aguilar-Vázquez, Andrea, Anda, Jesús-Aureliano Robles-De , Molberg, Øyvind , Dastmalchi, Maryam, Notarnicola, Antonella , Gheorghe, Karina, Liden, Maria, Hanna, Balsam , Jalal, Awat, Hellström, Helena, Martineus, Jehns Christian, New, Paul, Platt, Hazel, Ahmed, Yasmeen , Armstrong, Raymond, Bernstein, Robert, Black, Carol M., Butler, Robin, Carty, John , Chattopadhyay, Chandra, Chelliah, E G, Clarke, Fiona, Dawes, P. T., Devlin, Joseph, Edwards, Christopher, Emery, Paul , Fordham, J. L. A., Fraser, Alexander, Gaston, Hill, Gordon, Patrick , Griffiths, Bridget , Gunawardena, Harsha , Hall, Frances, Hanna, Michael G. , Harrison, Beverley, Hay, Elaine M. , Hilton‐Jones, David, Horden, Lesley, Jones, Adrian, Kamath, Sanjeet, Kennedy, Thomas J. , Klimiuk, P S, Knights, Sally, Lambert, John, Laxminarayan, Ramasharan, Lecky, Bryan, Marks, Jeffrey M., Martin, Michael F., McGonagle, Dennis , McHugh, Neil, McKenna, Francis, McLaren, John, McMahon, Michael , McRorie, Euan , Merry, P, Miller, James , Nicholls, Anne, Ong, Voon , Over, K. E., Packham, John, Pipitone, Nicolo, Plant, Michael, Pountain, G., Pullar, T, Roberts, Mark, Scott, David A. , Shadforth, M F, Sheeran, Thomas, Srinivasan, Arul, Swinson, David, Teh, Lee‐Suan , Webley, M, Winer, Jonathan M., Wedderburn, Lucy R. , Lilleker, James B , Lamb, Janine A , Oldroyd, Alexander G S , Wedderburn, Lucy R , Griger, Zoltan , Nguyen Thi Phuong, Thuy , Kodishala, Chanakya , Vazquez-Del Mercado, Monica , De Paepe, Boel , McHugh, Neil , Vencovsky, Jiri , Lundberg, Ingrid E , Chinoy, Hector , McCann, Liza J , Bleecker, Jan De , Vencovský, Jiří , Registry, MYONET, Mann, H. , Kryštůfková, Olga , Klein, Martin , Saavedra, Miguel A , Lastra, Olga Lidia Vera , Satoh, Minoru , Petri, Marcelo H. , Rönnelid, Johan , Lan, Nguyễn Thị Ngọc , Padyukov, Leonid , Rothwell, Simon W. , Bernstein, Robert, Bowman, Simon , Bruce, Ian N , Carty, John, Denton, Christopher P. , Edwards, Christopher, Fordham, John, Isaacs, John Dudley , Isenberg, David , Kitas, George D. , Lanyon, Peter , Luqmani, Raashid Ahmed , Machado, Pedro , Marks, Jeffrey, Martin, Michael, McHugh, Neil, Miles, Sarah, Nixon, Jennifer, Ong, Voon, Packham, John, Pipitone, Nicolo, Sanders, Paul W. , Williams, Brian, Winer, Jonathan

Mayo Clinic

Rheumatology | September 11, 2023 | Volume: 63 | Issue: 8 | Pages: 2093-2100

10.1093/rheumatology/kead481 | PMID 37698987 Get It

Abstract Objectives To compare clinical characteristics, including the frequency of cutaneous, extramuscular manifestations and malignancy, between adults with anti-synthetase syndrome (ASyS) and DM. Methods Using data regarding adults from the MYONET registry, a cohort of DM patients with anti-Mi2/-TIF1γ/-NXP2/-SAE/-MDA5 autoantibodies, and a cohort of ASyS patients with anti-tRNA synthetase autoantibodies (anti-Jo1/-PL7/-PL12/-OJ/-EJ/-Zo/-KS) were identified. Patients with DM sine dermatitis or with discordant dual autoantibody specificities were excluded. Sub-cohorts of patients with ASyS with or without skin involvement were defined based on presence of DM-type rashes (heliotrope rash, Gottron’s papules/sign, violaceous rash, shawl sign, V-sign, erythroderma, and/or periorbital rash). Results In total 1054 patients were included (DM, n = 405; ASyS, n = 649). In the ASyS cohort, 31% (n = 203) had DM-type skin involvement (ASyS-DMskin). A higher frequency of extramuscular manifestations, including Mechanic’s hands, Raynaud’s phenomenon, arthritis, interstitial lung disease and cardiac involvement differentiated ASyS-DMskin from DM (all P < 0.001), whereas higher frequency of any of four DM-type rashes—heliotrope rash (n = 248, 61% vs n = 90, 44%), violaceous rash (n = 166, 41% vs n = 57, 9%), V-sign (n = 124, 31% vs n = 28, 4%), and shawl sign (n = 133, 33% vs n = 18, 3%)—differentiated DM from ASyS-DMskin (all P < 0.005). Cancer-associated myositis (CAM) was more frequent in DM (n = 67, 17%) compared with ASyS (n = 21, 3%) and ASyS-DMskin (n = 7, 3%) cohorts (both P < 0.001). Conclusion DM-type rashes are frequent in patients with ASyS; however, distinct clinical manifestations differentiate these patients from classical DM. Skin involvement in ASyS does not necessitate increased malignancy surveillance. These findings will inform future ASyS classification criteria and patient management.
Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)
Cho, Hanna , Mundada, Nidhi S. , Apostolova, Liana G. , Carrillo, María C. , Shankar, Ranjani , Amuiri, Alinda, Zeltzer, Ehud , Windon, Charles , Soleimani‐Meigooni, David N. , Tanner, Jeremy A. , Lesman‐Segev, Orit H. , Aisen, Paul , Eloyan, Ani , Lee, Hye Sun , Hammers, Dustin B. , Kirby, Kala, Dage, Jeffrey L. , Fagan, Anne M. , Grinberg, Lea T. , Jack, Clifford R. , Kramer, Joel H. , Kukull, Walter A. , Vemuri, Prashanthi , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Stephen , Sha, Sharon, Turner, Raymond Scott , Wingo, Thomas S. , Joie, Renaud La , Rabinovici, Gil D. , Jack, Clifford R , Vemuri, Prashanthi , Day, Gregory S , La Joie, Renaud , Grinberg, Lea , Rabinovici, Gil D , Windon, Charles , Wingo, Thomas S , Dage, Jeffrey L , Lawhn-Heath, Courtney A. , Hammers, Dustin B , Foroud, Tatiana , Murray, Melissa E. , Nudelman, Kelly , Toga, Arthur W. , Atri, Alireza , Duara, Ranjan , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Sha, Sharon J. , Wolk, David A. , Koeppe, Robert A. , Iaccarino, Leonardo , Dickerson, Bradford Clark

Mayo Clinic

Alzheimer's & Dementia | September 10, 2023 | Volume: 19 | Issue: S9 | Pages: No page available

10.1002/alz.13453 | PMID 37690109 Get It

Abstract INTRODUCTION We aimed to describe baseline amyloid‐beta (Aβ) and tau‐positron emission tomograrphy (PET) from Longitudinal Early‐onset Alzheimer's Disease Study (LEADS), a prospective multi‐site observational study of sporadic early‐onset Alzheimer's disease (EOAD). METHODS We analyzed baseline [18F]Florbetaben (Aβ) and [18F]Flortaucipir (tau)‐PET from cognitively impaired participants with a clinical diagnosis of mild cognitive impairment (MCI) or AD dementia aged < 65 years. Florbetaben scans were used to distinguish cognitively impaired participants with EOAD (Aβ+) from EOnonAD (Aβ−) based on the combination of visual read by expert reader and image quantification. RESULTS 243/321 (75.7%) of participants were assigned to the EOAD group based on amyloid‐PET; 231 (95.1%) of them were tau‐PET positive (A+T+). Tau‐PET signal was elevated across cortical regions with a parietal‐predominant pattern, and higher burden was observed in younger and female EOAD participants. DISCUSSION LEADS data emphasizes the importance of biomarkers to enhance diagnostic accuracy in EOAD. The advanced tau‐PET binding at baseline might have implications for therapeutic strategies in patients with EOAD. HIGHLIGHTS 72% of patients with clinical EOAD were positive on both amyloid‐ and tau‐PET. Amyloid‐positive patients with EOAD had high tau‐PET signal across cortical regions. In EOAD, tau‐PET mediated the relationship between amyloid‐PET and MMSE. Among EOAD patients, younger onset and female sex were associated with higher tau‐PET.
A pilot genome‐wide association study meta‐analysis of gastroparesis
Tavares, Letícia Camargo , Kwicklis, Madeline , Pandit, Anita , Pullapantula, Suraj R., Bernard, Cheryl E., Marques, Francine Z. , Shulman, Robert J. , Koch, Kenneth L. , Sarosiek, Irene , McCallum, Richard W. , Pasricha, Pankaj J. , Hamilton, Frank A., Tonascia, James , Zawistowski, Matthew , Farrugia, Gianrico , Grover, Madhusudan , Pullapantula, Suraj, Bernard, Cheryl, Farrugia, Gianrico , Grover, Madhusudan , Camargo Tavares, Leticia , Zheng, Tenghao , Mitchell, Emily, Teder‐Laving, Maris , Esko, Tõnu , Kuo, Braden , Chumpitazi, Bruno P. , Abell, Thomas L. , Parkman, Henry P. , D’Amato, Mauro

Mayo Clinic

United European Gastroenterology Journal | September 9, 2023 | Volume: 11 | Issue: 8 | Pages: 784-796

10.1002/ueg2.12453 | PMID 37688361 Get It

AbstractBackgroundGastroparesis (GP) is characterized by delayed gastric emptying in the absence of mechanical obstruction.ObjectiveGenetic predisposition may play a role; however, investigation at the genome‐wide level has not been performed.MethodsWe carried out a genome‐wide association study (GWAS) meta‐analysis on (i) 478 GP patients from the National Institute of Diabetes and Digestive and Kidney Diseases Gastroparesis Clinical Research Consortium (GpCRC) compared to 9931 population‐based controls from the University of Michigan Health and Retirement Study; and (ii) 402 GP cases compared to 48,340 non‐gastroparesis controls from the Michigan Genomics Initiative. Associations for 5,811,784 high‐quality SNPs were tested on a total of 880 GP patients and 58,271 controls, using logistic mixed models adjusted for age, sex, and principal components. Gene mapping was obtained based on genomic position and expression quantitative trait loci, and a gene‐set network enrichment analysis was performed. Genetic associations with clinical data were tested in GpCRC patients. Protein expression of selected candidate genes was determined in full thickness gastric biopsies from GpCRC patients and controls.ResultsWhile no SNP associations were detected at strict significance (p ≤ 5 × 10−8), nine independent genomic loci were associated at suggestive significance (p ≤ 1 × 10−5), with the strongest signal (rs9273363, odds ratio = 1.4, p = 1 × 10−7) mapped to the human leukocyte antigen region. Computational annotation of suggestive risk loci identified 14 protein‐coding candidate genes. Gene‐set network enrichment analysis revealed pathways potentially involved in immune and motor dysregulation (pFDR ≤ 0.05). The GP risk allele rs6984536A (Peroxidasin‐Like; PXDNL) was associated with increased abdominal pain severity scores (Beta = 0.13, p = 0.03). Gastric muscularis expression of PXDNL also positively correlated with abdominal pain in GP patients (r = 0.8, p = 0.02). Dickkopf WNT Signaling Pathway Inhibitor 1 showed decreased expression in diabetic GP patients (p = 0.005 vs. controls).ConclusionWe report preliminary GWAS findings for GP, which highlight candidate genes and pathways related to immune and sensory‐motor dysregulation. Larger studies are needed to validate and expand these findings in independent datasets.
P14.05.B 2-HYDROXYGLUTARATE IN CEREBROSPINAL FLUID AS A MONITORING BIOMARKER FOR IDH-MUTANT GLIOMAS
Riviere-Cazaux, Cécile , Lacey, Joshua , Carlstrom, Luke, Laxen, William , Munoz-Casabella, Amanda , Hoplin, Matthew D. , Ikram, S. , Zubair, Abdullah Bin, Andersen, Katherine, Warrington, A.P., Decker, Paul A. , Campian, Jian , Eckel‐Passow, Jeanette E. , Kizilbash, Sani H. , Tortorelli, Silvia , Kizilbash, Sani H , Lacey, J, Carlstrom, L, Ikram, S, Warrington, A, Decker, Paul A. , Kaufmann, Thomas , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | September 8, 2023 | Volume: 25 | Issue: Supplement_2 | Pages: ii106-ii106

10.1093/neuonc/noad137.356 Get It

Abstract BACKGROUND D-2-hydroxyglutarate (D-2-HG) is a well-established oncometabolite of isocitrate dehydrogenase (IDH) mutant gliomas. While prior studies have demonstrated that D-2-HG is elevated in the cerebrospinal fluid (CSF) of patients with IDH-mutant gliomas, no study has evaluated the ability of CSF D-2-HG to quantitatively monitor tumor burden and therapeutic response. Toward this goal, we are routinely obtaining CSF samples from patients prior to, during, and after treatment via intra-operative collection and CSF-access devices. MATERIAL AND METHODS Patients were enrolled into our Ommaya reservoir study (NCT04692337), which enables longitudinal access to CSF. The catheter for the implanted reservoir was placed within the surgical resection cavity following a standard-of-care resection. Intra-operatively collected CSF samples were also biobanked through Mayo Clinic’s Neuro-Oncology biorepository. CSF samples were also acquired via clinically indicated ventriculoperitoneal shunts (VP shunts) or external ventricular drains via our ongoing CSF biomarkers study (NCT04692324). D-and-L-2-HG were assayed from each CSF sample via gas chromatography-mass spectrometry (GC-MS) at Mayo Clinic’s Biochemical Genetics Laboratory. RESULTS CSF was collected prior to and after resection in patients via Ommaya reservoirs or VP shunts, all of whom underwent near gross total resections (&gt;95% of tumor volume). D-2-HG and the D/L ratio fell on average by 57.9% (range: 15.1%-98.6%) and 68.8% (range: 49.3%-98.9%), respectively, following resection. In one patient with a largely intraventricular grade 4 IDH-mutant astrocytoma, D-and-L-2-HG fell by 99.1% and 99.3% by post-operative day 2, consistent with the impact of ventricular contact on baseline CSF D-2-HG levels. In patients for whom CSF was collected throughout chemoradiation, with or without immunotherapy, D-2-HG and the D/L ratio continued to decrease over time, despite concern for pseudoprogression versus progression on imaging. CONCLUSION Our early experience with this strategy demonstrates the potential for intracranial CSF D-2-HG as a monitoring biomarker for IDH-mutant gliomas. Work is ongoing to evaluate the reproducibility of these findings in a larger cohort of patients with low or high-grade gliomas, in addition to the impact of tumor recurrence on 2-HG. Future studies will evaluate the impact of IDH inhibitors and other experimental therapies on CSF 2-HG levels for pharmacodynamic monitoring of treatment response.